Results 111 to 120 of about 74,852 (258)

PARP inhibitors as precision medicine for cancer treatment

, 2017
Personalized or precision medicine is an emerging treatment approach tailored to individuals or certain groups of patients based on their unique characteristics.
Hirohito Yamaguchi, Jennifer L. Hsu, Yi Du, Mien-Chie Hung   +3 more
core   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

Chemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright   +9 more
wiley   +1 more source

PARP inhibitors for cancer treatment

, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer agents to be used either alone or in combination with chemotherapy and radiotherapy.
GRAZIANI, GRAZIA
core  

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer

, 2023
Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer, Amy Bodrog, MD, Lipson Cancer Institute Objectives: Discuss how PARP inhibitors work.
Bodrog, Amy
core  

Aloe vera in Food Preservation: Harnessing Bioactive Constituents for Clean‐Label Innovation and Safety Assurance

Food Safety and Health, EarlyView.
Aloe vera‐derived biopolymers and nanoformulations enhance antimicrobial, antioxidant, and barrier functions in clean‐label edible coatings and films, whereas safety‐critical anthraquinone thresholds and regulatory constraints shape their translational potential.
Acharya Balkrishna, Hemant Sharma, Sonam Verma, Amar Jeet, Sumit Kumar Singh, Sharad Kumar Tripathi, Vedpriya Arya   +6 more
wiley   +1 more source

Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers

, 2015
This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer.
Eric Van Cutsem, Hilary Calvert, Andrew Tutt, Tristin Abair, Nicoletta Colombo, Eric Pujade-Lauraine   +5 more
core  

Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice.

, 2005
Poly(ADP-ribose) polymerase-1 (PARP) inhibitors have been investigated as enhancers of chemotherapy. We recently showed that PARP inhibitor GPI 15427 increases the anti-tumor efficacy of temozolomide (TMZ) in mice. To select a PARP inhibitor for clinical
C. Leonetti, M. Vergati, Tentori, L, J. Zhang, G. Graziani, GRAZIANI, GRAZIA, Vergati, M, TENTORI, LUCIO, M. Scarsella, Graziani, G, A. Muzi, Leonetti, C, and and the Guilford PARP Project Group, Scarsella, M, Muzi, A, Lapidus, RG, MUZI, ALESSIA, L. Tentori, R. G. Lapidus, and the Guilford PARP Project Group, Zhang, J   +20 more
core   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

PARP inhibition preserves cone photoreceptors in rd2 retina

Acta Neuropathologica Communications
The rd2 mouse model, characterized by a mutation in the Prph2 gene, exhibits abnormal development of photoreceptor outer segments, resulting in progressive retinal degeneration. While the correlation between poly-ADP-ribose polymerase (PARP) activity and
Pakize Nur Akkaya, María Miranda, Inmaculada Almansa, Cigdem Elmas, Dragana Trifunovic, Zohreh Hosseinzadeh, Ayse Sahaboglu   +6 more
doaj   +1 more source